Twice-Yearly Eczema Shots Maintain 85% Clearance, Data Show

Apogee Therapeutics released 52-week maintenance data for zumilokibart, its anti-IL-13 antibody for moderate-to-severe atopic dermatitis. The headline: patients who responded at 16 weeks stayed clear with just two to four injections per year. In an eczema market built around biweekly shots, that's not an incremental improvement — it's a different treatment architecture.

The numbers

The Phase 2 APEX trial Part A enrolled 123 adult patients randomized 2:1 to zumilokibart versus placebo. At 16 weeks, zumilokibart posted EASI-75 of 66.9% versus 24.6% on placebo — which Apogee called the highest for any biologic in a global atopic dermatitis study. Those were the induction results from July 2025.

Today's data is about what happened next. Among patients who achieved response at Week 16 and rolled into maintenance dosing:

Quarterly dosing (every three months): EASI-75 of 75%, vIGA 0/1 of 86%.

Six-month dosing (twice a year): EASI-75 of 85%, vIGA 0/1 of 78%.

No new safety signals. The drug was well tolerated through 52 weeks, consistent with the class profile.

The stock jumped roughly 19% on the data, adding about $728 million in market cap.

The dosing arms race, explained

To understand why these numbers matter, you need the competitive landscape — and specifically, you need to count injections.

Dupixent (dupilumab, Sanofi/Regeneron) is the incumbent: every two weeks, indefinitely. That's 26 injections a year. It generated $11.6 billion in global sales in 2023 and is on pace for substantially more. It works. Patients tolerate it. But biweekly self-injection forever is a real burden, and it's a barrier to adherence.

Ebglyss (lebrikizumab, Lilly) arrived as the first challenger: approved at every four weeks for maintenance, with data supporting every eight weeks. That cuts the burden by half to three-quarters. Better, but still monthly or bimonthly.

Amlitelimab (Sanofi, in Phase 3) works by a different mechanism — OX40L inhibition rather than IL-13 blocking — and is being tested at every 12 weeks. That's roughly four injections a year. Sanofi is essentially building the replacement for its own franchise, hedging against exactly the kind of dosing disruption Apogee represents.

And now zumilokibart: potentially every three to six months. Two to four injections per year. If these numbers hold in Phase 3, this isn't just a dosing convenience play — it changes the economics and logistics of treatment. For patients, fewer clinic visits or self-injections. For payers, potentially fewer adherence-related complications. For dermatologists, a fundamentally different monitoring cadence.

The caveats, honestly stated

Part A had 123 patients. The maintenance arms are smaller subsets of that — we're talking about response rates in responders, not the full intent-to-treat population. The six-month arm showing 85% EASI-75 versus 75% for quarterly dosing is counterintuitive (less frequent dosing producing better results?) and almost certainly reflects small-sample variance rather than a real biological signal. These numbers will bounce around in larger studies.

Apogee is Phase 2. Phase 3 is planned for the second half of 2026. That's at least two to three years from market, assuming everything goes right. Dupixent and Ebglyss are available now. Amlitelimab has a head start in Phase 3.

And there's an important nuance in what "best-in-class" means in this context. Apogee's 66.9% induction EASI-75 is impressive on a cross-trial comparison, but cross-trial comparisons are inherently imprecise — different patient populations, different placebo rates, different background therapies. Apogee is running a head-to-head trial (APG279) against Dupixent, expected to read out in the second half of 2026. That's the data that will actually settle the efficacy question.

Who's behind this

Apogee was founded in 2022 by Fairmount Funds and is led by CEO Michael Henderson, a physician-executive who previously ran Argenx, the company behind Vyvgart. The company went public in 2023 and has been systematically building a pipeline of long-acting biologics for large I&I markets — the thesis is that engineering antibodies for extended half-life can fundamentally shift dosing paradigms. It's sitting on about $903 million in cash, enough to fund through Phase 3 data and beyond without dilution.

The approach is less about discovering new targets and more about optimizing delivery: take a validated mechanism (IL-13 for atopic dermatitis, where Dupixent proved the biology) and engineer a molecule that works as well or better with radically less frequent dosing. It's a bet on biological engineering over biological novelty.

What to watch

The two most important upcoming catalysts: APEX Part B (testing higher exposures, mid-2026 readout) and the APG279 head-to-head versus Dupixent (second half 2026). Part B could establish a higher efficacy ceiling. The head-to-head will either validate or deflate the "best-in-class" claim.

The broader picture: the atopic dermatitis market is entering a dosing disruption cycle. Within two years, clinicians could have options ranging from biweekly (Dupixent) to biannual (zumilokibart). That kind of spread doesn't just affect market share — it redefines what patients expect from chronic disease management. The question for Apogee is whether Phase 3 confirms what Phase 2 suggests. If it does, Dupixent's $11 billion franchise gets a lot more contested.